Abstract Number: 823 • 2017 ACR/ARHP Annual Meeting
Seasonal Variation in Giant Cell Arteritis and Polymyalgia Rheumatica Hospitalizations: Data from Nationwide Inpatient Sample
Background/Purpose: Most studies looking at seasonal variations in giant cell arteritis (GCA) note a seasonal trend, but show disparity on timing. Concurrent peaks of GCA…Abstract Number: 786 • 2017 ACR/ARHP Annual Meeting
Smoking As a Risk Factor for Giant Cell Arteritis: A Systematic Review and Meta-Analysis
Background/Purpose: Tobacco smoking is a well-established risk factor for the development of several autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus. A similar…Abstract Number: 892 • 2017 ACR/ARHP Annual Meeting
Health-Related Quality of Life in Patients with Giant Cell Arteritis Treated with Tocilizumab in a Randomized Controlled Phase 3 Trial
Background/Purpose: Superior rates of sustained glucocorticoid (GC)–free remission were shown in patients with giant cell arteritis (GCA) treated with weekly (QW) or every-other-week (Q2W) subcutaneous…Abstract Number: 787 • 2017 ACR/ARHP Annual Meeting
Prevalence of Relapses of Giant Cell Arteritis in Patients Treated with Corticosteroids: A Meta-Analysis
Background/Purpose: The relapse rate of giant cell arteritis (GCA) in the patients treated by corticosteroids (CS) varied widely in observational series and randomized trials. The…Abstract Number: 1734 • 2017 ACR/ARHP Annual Meeting
CXCR5+ CD4 T Cells Signature Differentiates Takayasu Arteritis from Giant Cell Arteritis
Background/Purpose: To compare microarray gene analysis of patients with Giant cell arteritis to patients with Takayasu arteritis. Methods: We performed comparative microarray gene analysis of…Abstract Number: 790 • 2017 ACR/ARHP Annual Meeting
Pre-Clinical Evidences of Immunomodulatory Activities of Tuftsin-Phosphorylcholine on Samples from Patients with Giant Cell Arteritis in Comparison to Corticosteroids
Background/Purpose: Tuftsin-PhosphorylCholine (TPC) is a novel bi-specific molecule which has shown immunomodulatory effects in experimental mouse models of lupus, colitis and arthritis but data in…Abstract Number: 2932 • 2017 ACR/ARHP Annual Meeting
mTOR Pathway Is Activated in Endothelial Cells from Patients with Takayasu Arteritis and Is Modulated By Serum IgG
Background/Purpose: Takayasu arteritis (TA) and giant cell arteritis (GCA) are large-vessel vasculitis characterized by vascular remodelling involving endothelial cells (ECs) and vascular smooth muscle cells,…Abstract Number: 791 • 2017 ACR/ARHP Annual Meeting
Aortic Dilatation in Patients with Large Vessel Vasculitis: A Longitudinal Case Control Study Using Positron Emission Tomography/Computed Tomography
Background/Purpose: To evaluate aortic diameter and predictors of aortic dilatation using FDG-PET/CT in a longitudinally followed cohort of patients with large vessel vasculitis (LVV) compared…Abstract Number: 793 • 2017 ACR/ARHP Annual Meeting
Metotrexate in the Treatment of Giant Cell Arteritis: To be or Not to be
Background/Purpose: The high-dose glucocorticoids (GCs) are the mainstay of treatment in Giant Cell Arteritis (GCA). Patients treated with greater GC dosages are at the greatest…Abstract Number: 795 • 2017 ACR/ARHP Annual Meeting
Characteristics and Treatment Outcomes of Giant Cell Arteritis with Large-Vessel Lesions in a Nationwide, Retrospective Cohort Study in Japan
Background/Purpose: Giant cell arteritis (GCA) often affects aorta or its branches, but it is unclear whether the large-vessel (LV) lesions are associated with treatment outcomes.…Abstract Number: 796 • 2017 ACR/ARHP Annual Meeting
Presentation and Outcome of Large-Vessel Vasculitis Diagnosed between 50 and 60 Years: Case-Control Study Based on 183 Cases
Background/Purpose: Primary large-vessel vasculitis (LVV) include giant cell arteritis (GCA) and Takayasu arteritis (TA). Age at onset is commonly used to distinguish GCA and TA.…Abstract Number: 797 • 2017 ACR/ARHP Annual Meeting
Temporal Arteritis Revealing Antineutrophil Cytoplasmic Antibody–Associated Vasculitides: A Retrospective Study of 50 Cases
Background/Purpose: Giant cell arteritis (GCA) is a non-necrotizing granulomatous arteritis involving large vessels, whereas antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitides (AAV) are a group of necrotizing…Abstract Number: 259 • 2017 ACR/ARHP Annual Meeting
Imaging for Diagnosis, Monitoring and Outcome Prediction of Large Vessel Vasculitis: A Systematic Review of the Literature and Meta-Analysis Informing the EULAR Recommendations
Background/Purpose: Modern imaging techniques including ultrasound (US), magnetic resonance imaging (MRI), computed tomography (CT) and 18F-FDG positron emission tomography (PET) are increasingly studied in large…Abstract Number: 799 • 2017 ACR/ARHP Annual Meeting
Acetylcholinesterase Is Highly Expressed in the Inflamed Vessel Wall of Patients with Giant Cell Arteritis
Background/Purpose: The temporal artery biopsy (TAB) remains the gold standard in the diagnosis of giant cell arteritis (GCA). However, TABs are false-negative in 40% of…Abstract Number: 261 • 2017 ACR/ARHP Annual Meeting
Ultrasound CUT-Off in GIANT CELL Arteritis a Solution to Arteriosclerosis Pitfall in the Halo Sign
Background/Purpose: At the age of Giant Cell Arteritis (GCA) atherosclerosis is common. The ultrasonographic (US) appearance of athermanous plaque is usually easily differentiated from the…
- « Previous Page
- 1
- …
- 23
- 24
- 25
- 26
- 27
- …
- 32
- Next Page »